South China Morning Post
International · 2 hrs ago
AI scored
Hongkongers to pay only HK$240 a year for leukaemia drug after system shake-up
82Accuracy
centreBias
0Ratings
💬 0Comments
AI Analysis
Accuracy 82/100
Partisan intensity 15/100
ObjectivePartisan
Centre / Neutral ✓ Fair headline
Hong Kong's Hospital Authority has begun subsidising the leukaemia drug Dasatinib, reducing patient costs from up to HK$500,000 annually to HK$240, benefiting over 400 cancer patients with government funding of HK$49 million per year.
Hongkongers to pay only HK$240 a year for leukaemia drug after system shake-up
More than 400 cancer patients are set to benefit from Hong Kong health authorities’ decision to subsidise a leukaemia drug, and will go from paying up to HK$500,000 (US$63,800) a year for treatment to forking out just HK$240.
The Hospital Authority said on Wednesday that it began subsidising the medication, Dasatinib, in April, with the government expected to set aside an additional HK$49 million in annual spending to help cover the cost.
As part of the move, Dasatinib was reclassified from a...
Discussion 0 comments
Sort:
?
No comments yet — be the first to start the discussion!